Lakefront Biotherapeutics NV (LKFT) Key Metrics
LKFT key metrics, 2021–2025
Fiscal year ended December 31, 2025 · eurosLKFT returns How much profit the business earns on the capital it uses.
LKFT financial health Debt, liquidity and how easily interest is covered.
LKFT efficiency & capital use Working capital cycle and where the cash goes.
LKFT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
LKFT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
LKFT key metrics in euros
2021–2025| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Returns & profitability | |||||
| Return on equity (ROE) | 10.5% | 2.6% | 8.0% | −8.6% | — |
| Return on invested capital (ROIC) | 32.6% | −5.4% | −1.9% | −5.1% | — |
| Return on assets (ROA) | 8.5% | 1.7% | 4.7% | −4.6% | — |
| Return on tangible assets | 9.4% | 1.9% | 5.1% | −4.8% | — |
| Free cash flow margin | −24.4% | −145.9% | −177.4% | −222.8% | — |
| Income quality (OCF / net income) | −0.80 | −4.32 | −1.92 | — | — |
| Financial health | |||||
| Total debt | €6.9M | — | — | — | — |
| Cash & short-term investments | €3.00B | €64.2M | €166.8M | €508.1M | — |
| Net debt | −€2.99B | −€64.2M | −€166.8M | −€508.1M | — |
| Debt / equity | 0.00 | — | — | — | — |
| Debt / assets | 0.00 | — | — | — | — |
| Net debt / EBITDA | −8.33 | −1.48 | −3.27 | −131.23 | — |
| Current ratio | 20.15 | 9.97 | 9.02 | 8.11 | — |
| Quick ratio | 20.00 | 9.81 | 8.84 | 8.01 | — |
| Interest coverage | 226.2 | -206.7 | -49.9 | -14.3 | -19.7 |
| Working capital | €2.93B | €3.00B | €3.43B | €3.71B | — |
| Invested capital | €244.7M | €2.83B | €2.63B | €2.02B | — |
| Tangible asset value | €3.24B | €2.66B | €2.60B | €2.31B | — |
| Net current asset value | €2.91B | €2.10B | €2.30B | €2.03B | — |
| Capital allocation | |||||
| Capex / revenue | 1.2% | 29.8% | 8.0% | 15.3% | — |
| Capex / depreciation | 0.25 | 1.80 | 0.44 | 0.56 | — |
| Stock-based compensation / revenue | 2.2% | 7.2% | 23.7% | 36.7% | — |
| R&D / revenue | 41.3% | 121.7% | 100.7% | 111.8% | 136.7% |
| SG&A / revenue | 10.1% | 35.1% | 38.6% | 42.8% | 54.5% |
| Efficiency | |||||
| Days sales outstanding | 14.1 | 33.1 | 34.8 | 42.7 | — |
| Days of inventory on hand | 452.2 | 655.2 | — | — | — |
| Days payables outstanding | 594.4 | 1,041.1 | — | — | — |
| Cash conversion cycle (days) | -128.1 | -352.8 | — | — | — |
| Receivables turnover | 25.96 | 11.03 | 10.49 | 8.56 | — |
| Payables turnover | 0.61 | 0.35 | 0.00 | 0.00 | — |
| Inventory turnover | 0.81 | 0.56 | 0.00 | 0.00 | — |
| Asset turnover | 0.29 | 0.06 | 0.05 | 0.05 | — |
| Average receivables | €42.8M | €25.0M | €22.8M | €28.2M | — |
| Average payables | €48.4M | €99.4M | €134.0M | €133.3M | — |
| Average inventory | €36.8M | €62.6M | €63.5M | €52.9M | — |
| Intangibles / total assets | 0.0% | 5.7% | 4.5% | 4.6% | — |
Computed from LKFT's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in euros; data from EODHD. Averages use the opening and closing balance of each year.
LKFT valuation and financial ratios
Lakefront Biotherapeutics earned a return on equity of 10.5% and a return on invested capital of 32.6% in fiscal 2025. It ended the year with €6.9 million of debt and €3.0 billion in cash and short-term investments, a net cash position of €3.0 billion.
See the LKFT income statement, the LKFT chart for price history, or the LKFT stock overview for the latest quote and news.
LKFT key metrics FAQ
What is Lakefront Biotherapeutics's return on equity?
Lakefront Biotherapeutics's return on equity (ROE) was 10.5% in fiscal 2025: net income of €320.9 million on average shareholders' equity of €3.1 billion.
What is Lakefront Biotherapeutics's ROIC?
Lakefront Biotherapeutics's return on invested capital was 32.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Lakefront Biotherapeutics have?
Lakefront Biotherapeutics had total debt of €6.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Lakefront Biotherapeutics's current ratio?
Lakefront Biotherapeutics's current ratio was 20.15 at the end of fiscal 2025: current assets were 20.15 times current liabilities.